UROGEN PHARMA
UroGen Pharma (formerly Theracoat ) (“UroGen” or “the Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The Company has an innovative and broad pipeline of product candidates that it believes can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The lead product candidates, ... MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant, post-surgery, therapy. The Company’s clinical stage pipeline includes Vesimune, its proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. In addition, BotuGel is a proprietary novel RTGel-based formulation of BOTOX, a branded drug, that it believes can potentially serve as an effective treatment option for patients suffering from overactive bladder. UroGen has licensed the worldwide rights to BotuGel to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, which plans to commence a Phase 2 clinical trial of BotuGel.
UROGEN PHARMA
Industry:
Biopharma Biotechnology Clinical Trials Life Science Pharmaceutical
Founded:
2004-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.urogen.com
Total Employee:
101+
Status:
Active
Contact:
1(646)768-9780
Total Funding:
529.6 M USD
Technology used in webpage:
IPv6 U.S. Server Location Microsoft COVID-19 Microsoft Azure Akamai Hosted Microsoft Azure Europe West Region YourAdChoices.com
Similar Organizations
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Current Advisors List
Board_member
2023-07-01
Current Employees Featured
Bryon Wornson Vice President @ UroGen Pharma
Vice President
2022-04-01
Mark Schoenberg Chief Medical Officer @ UroGen Pharma
Chief Medical Officer
David Lin Chief Commercial Officer @ UroGen Pharma
Chief Commercial Officer
2024-06-01
Jeff Bova Chief Commercial Officer @ UroGen Pharma
Chief Commercial Officer
2020-04-15
Hamza Sheikh Director of BD, Strategy, and Commercial Development @ UroGen Pharma
Director of BD, Strategy, and Commercial Development
2021-02-01
Liz Barrett CEO @ UroGen Pharma
CEO
2019-01-01
Elyse Seltzer Chief Development Officer @ UroGen Pharma
Chief Development Officer
2020-04-15
Jason Smith General Counsel and Chief Compliance Officer @ UroGen Pharma
General Counsel and Chief Compliance Officer
2020-08-01
Polly Murphy Chief Business Officer @ UroGen Pharma
Chief Business Officer
2020-09-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-01-01 | Telormedix | Telormedix acquired by UroGen Pharma | N/A |
Investors List
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - UroGen Pharma
RTW Investments
RTW Investments investment in Post-IPO Equity - UroGen Pharma
Two River
Two River investment in Series A - UroGen Pharma
Pontifax
Pontifax investment in Series A - UroGen Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2024-06-03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer |
| 2020-04-15 | UroGen Makes Chief Commercial & Chief Development Officer Promotions |
Official Site Inspections
http://www.urogen.com Semrush global rank: 2.39 M Semrush visits lastest month: 8.03 K
- Host name: acd89244c803f7181.awsglobalaccelerator.com
- IP address: 75.2.60.5
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "UroGen Pharma"
UroGen Pharma | Corporate Responsibility
UroGen has tailored its CCP to the size, organization structure, and business operations of UroGen. ... UroGen will continually evaluate and update its CCP as necessary and appropriate …See details»
UroGen Pharma | What We Stand For
We're a tight-knit—and growing!—team of dreamers and doers who are passionate about making a difference. We ensure transparency through an open-door policy and through internal organizations like the UroGen Culture …See details»
UroGen Pharma | Leadership
Dr. Belldegrun is the Chairman of UroGen Pharma and has served as our Chair since December 2012. He has built a distinguished career as a visionary surgeon, scientist, and life sciences …See details»
Governance Overview | UroGen Pharma, Ltd
The Board of Directors of UroGen ® Pharma (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of …See details»
UroGen Pharma - Crunchbase Company Profile
UroGen Pharma (formerly Theracoat ) (“UroGen” or “the Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies …See details»
Investor Relations - UroGen Pharma, Ltd
Mar 10, 2025 Corporate profile. UroGen ® is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because …See details»
UroGen Org Chart + Executive Team - The Official Board
Organizational Chart of UroGen. UroGen Org Chart www.urogen.com. has 15 executives +1 646 768 9780; Add an executive. UroGen (URGN) News . Anything missing? We search for you. …See details»
UroGen Pharma - Leadership Team - The Org
The Leadership Team at UroGen Pharma is responsible for shaping the strategic direction of the company, overseeing operations across manufacturing, research, and clinical development, …See details»
UroGen Pharma - Org chart - The Org
Explore UroGen Pharma's organizational chart. Discover current team members including executives, board members, and advisors.See details»
UroGen Pharma
5 days ago UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 Read more …See details»
Urogen Pharma CEO and Key Executive Team | Craft.co
Urogen Pharma's President and Chief Executive Officer, Director is Liz Barrett. Other executives include Cynthia Butitta, Director; Jeff Bova, Chief Commercial Officer and 6 others. See the full …See details»
UroGen Pharma - Org Chart, Teams, Culture & Jobs - The Org
UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Industries. Biotechnology. Headquarters. Princeton, United States. Stage. Post IPO Debt. Employees. 51-200. Links. Org chart.See details»
UroGen Pharma - LinkedIn
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision ...See details»
UroGen Pharma - Funding, Financials, Valuation & Investors
UroGen Pharma is registered under the ticker NASDAQ:URGN . Their stock opened with $13.00 in its May 5, 2017 IPO. UroGen Pharma is funded by 4 investors. Pharmakon Advisors and …See details»
Urogen Pharma, Inc. - Building Novel Solutions That Treat …
UroGen Declaration of Compliance: California Health and Safety Code §§ 119400-119402 UroGen Pharma Inc. and UroGen Pharma Ltd. (collectively, “UroGen Pharma”) declares that, …See details»
UroGen Advances Long-Term Growth Strategy by Acquiring a Next ...
Feb 20, 2025 “UroGen’s long-term growth strategy is built on advancing our uro-oncology pipeline, expanding our portfolio, and driving innovation in cancer treatment,” said Liz Barrett, …See details»
Urogen Pharma - Craft
Oct 29, 2024 UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies …See details»
UroGen Pharma Announces Encouraging Results from a Phase 1 …
Apr 26, 2025 UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective …See details»
UroGen Pharma Ltd. - AnnualReports.com
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.See details»
UroGen Announces Updated 18-Month Duration of Response …
Apr 26, 2025 18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) Data unveiled during a Podium …See details»